Comparative Pharmacology
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus MINIPRESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus MINIPRESS.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE vs MINIPRESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors, inhibiting vasoconstriction and reducing peripheral vascular resistance.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
Initial: 1 mg orally 2-3 times daily. Maintenance: 2-5 mg orally 2-3 times daily. Maximum: 20 mg/day.
None Documented
None Documented
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
Terminal elimination half-life is 2-3 hours; clinical effect persists longer (up to 24 hours) due to sustained receptor binding.
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Primarily hepatic metabolism (90%) with <10% excreted unchanged in urine; 50-60% of metabolites eliminated in bile/feces, 40-50% in urine.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker